share_log

PDS Biotech To Event To Discuss Positive, Updated Data From Phase 2 VERSATILE-002 Clinical Trial With Versamune HPV In Combination With KEYTRUDA In Recurrent Or Metastatic Head And Neck Cancer

Moomoo 24/7 ·  Apr 23 08:01

Company to Host Key Opinion Leader Event on May 8 at 1:30pm ET to Discuss Updated Results of VERSATILE-002, Unmet Treatment Needs in Advanced Head and Neck Cancer and planned Triple Combination Trial

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment